DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Glipizide (Glipizide) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

In U.S. and foreign controlled studies, the frequency of serious adverse reactions reported was very low. Of 702 patients, 11.8% reported adverse reactions and in only 1.5% was glipizide discontinued.

Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections.

Gastrointestinal: Gastrointestinal disturbances are the most common reactions. Gastrointestinal complaints were reported with the following approximate incidence: nausea and diarrhea, one in seventy; constipation and gastralgia, one in one hundred. They appear to be dose-related and may disappear on division or reduction of dosage. Cholestatic jaundice may occur rarely with sulfonylureas: Glipizide should be discontinued if this occurs.

Dermatologic: Allergic skin reactions including erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, and eczema have been reported in about one in seventy patients. These may be transient and may disappear despite continued use of glipizide; if skin reactions persist, the drug should be discontinued. Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.

Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia (see PRECAUTIONS), aplastic anemia, and pancytopenia have been reported with sulfonylureas.

Metabolic: Hepatic porphyria and disulfiram-like reactions have been reported with sulfonylureas. In the mouse, glipizide pretreatment did not cause an accumulation of acetaldehyde after ethanol administration. Clinical experience to date has shown that glipizide has an extremely low incidence of disulfiram-like alcohol reactions.

Endocrine Reactions: Cases of hyponatremia and the syndrome of inappropriate anti-diuretic hormone (SIADH) secretion have been reported with this and other sulfonylureas.

Miscellaneous: Dizziness, drowsiness, and headache have each been reported in about one in fifty patients treated with glipizide. They are usually transient and seldom require discontinuance of therapy.

Hemolytic Anemia: Treatment of patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Because glipizide belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered. In postmarketing reports, hemolytic anemia has also been reported in patients who did not have known G6PD deficiency.

Laboratory Tests: The pattern of laboratory test abnormalities observed with glipizide was similar to that for other sulfonylureas. Occasional mild to moderate elevations of SGOT, LDH, alkaline phosphatase, BUN and creatinine were noted. One case of jaundice was reported. The relationship of these abnormalities to glipizide is uncertain, and they have rarely been associated with clinical symptoms.



REPORTS OF SUSPECTED GLIPIZIDE SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Glipizide. The information is not vetted and should not be considered as verified clinical evidence.

Possible Glipizide side effects / adverse reactions in 59 year old male

Reported by a pharmacist from United States on 2011-10-05

Patient: 59 year old male weighing 98.9 kg (217.6 pounds)

Reactions: Confusional State, Hypoglycaemia

Adverse event resulted in: hospitalization

Suspect drug(s):
Glipizide



Possible Glipizide side effects / adverse reactions in 73 year old male

Reported by a physician from United States on 2011-10-05

Patient: 73 year old male

Reactions: Renal Failure

Suspect drug(s):
Glipizide

Metformin HCL
    Dosage: for number of years



Possible Glipizide side effects / adverse reactions in 44 year old male

Reported by a physician from United States on 2011-10-05

Patient: 44 year old male

Reactions: Completed Suicide

Adverse event resulted in: death

Suspect drug(s):
Lisinopril
    Dosage: unk
    Administration route: Oral
    End date: 2007-01-01

Metformin HCL
    Dosage: unk
    Administration route: Oral
    End date: 2007-01-01

Pioglitazone
    Dosage: unk
    Administration route: Oral
    End date: 2007-01-01

Glipizide
    Dosage: unk
    Administration route: Oral
    End date: 2007-01-01



See index of all Glipizide side effect reports >>

Drug label data at the top of this Page last updated: 2010-06-02

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017